Results 71 to 80 of about 100,822 (314)

Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial. [PDF]

, 2016
BackgroundDecisions to stop randomized trials are often based on traditional P value thresholds and are often unconvincing to clinicians. To familiarize clinical investigators with the application and advantages of Bayesian monitoring methods, we ...
Bell, Edward F, Das, Abhik, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, Laptook, Abbot, Pedroza, Claudia, Shankaran, Seetha, Tyson, Jon E   +6 more
core  

InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients : the LIAISON study protocol [PDF]

, 2013
The study is funded by Chiesi Farmaceutici S.p.A., Parma, ItalyPeer reviewedPublisher ...
AC McLeish, AH Briggs, AH Liu, David Price, DE Morisky, DE Morisky, E Mehuys, ED Bateman, EF Juniper, EF Juniper, Eleonora Ingrassia, Fulvio Braido, G Bettoncelli, Gabriele Nicolini, Guy Brusselle, Heinrich Worth, HK Reddel, J Bousquet, J Haughney, JB Soriano, Joan B Soriano, KF Rabe, KF Rabe, L Allegra, L Cazzoletti, M Mintz, ML Levy, MR Partridge, Nicolas Roche, P Demoly, P Demoly, PJ Honkoop, PM O’Byrne, PO Ehrs, R De Marco, RA Nathan, RH Stanford, S Accordini, SA Williams, V Van der Meer   +39 more
core   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial [PDF]

, 2012
Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure.
A Mercat, AM Cheung, C Brun-Buisson, C Rossi, Cecilia M O’Kane, Christine McNally, Daniel F McAuley, DJ Kor, Excellence NIfHaC, F Gao Smith, Gavin D Perkins, GD Rubenfeld, GR Bernard, Grainne Crealey, Irish Critical Care Trials Group, John G Laffey, KF Schulz, LA Curtis, Lynn Murphy, M Shyamsundar, MA Matthay, Mark Cross, Michael Stevenson, MS Herridge, RG Brower, S Harvey, SE Erickson, T Craig, The ARDS Network investigators, The EuroQol Group, TR Craig, TW Felton   +31 more
core   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Security and confidentiality approach for the Clinical E-Science Framework (CLEF) [PDF]

, 2004
Objectives: CLEF is an MRC sponsored project in the E-Science programme that aims to establish methodologies and a technical infrastructure for the next generation of integrated clinical and bioscience research. Methods: The heart of the CLEF approach to
Detmer, D., Ingram, D., Kalra, D., MacKay, J., Milan, J., Rector, A., Singleton, P.   +6 more
core  

Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment Design and Cohort Baseline Characteristics of the German Dementia Competence Network [PDF]

, 2009
Background: The German Dementia Competence Network (DCN) has established procedures for standardized multicenter acquisition of clinical, biological and imaging data, for centralized data management, and for the evaluation of new treatments.
Frölich, Lutz, Gertz, Hermann-Josef, Hampel, Harald, Henn, Fritz, Heuser, Isabella, Huell, Michael, Jahn, Holger, Jessen, Frank, Kornhuber, Johannes, Luckhaus, Christian, Maier, Wolfgang, Pantel, Johannes, Perneczky, Robert, Peters, Oliver, Rienhoff, Otto, Ruüther, Eckart, Schmidtke, Klaus, Schroeder, Johannes, Seuchter, Susanne A., Weih, Markus, Wiltfang, Jens, Wolf, Stefanie   +21 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Comparison of the completed and discontinued pediatric drug clinical trials in Mainland China: a cross-sectional analysis based on the data from 2003 to 2023

BMC Pediatrics
Background Pediatric drug clinical trials are essential for ensuring the accessibility and safety of medications intended for children. In recent years, the Chinese government has implemented various measures to foster the development of pediatric drug ...
Zi-Ming Wang, Rui-Rui Du, Li Yang
doaj   +1 more source